• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙通道阻滞剂替帕米对快速钠内向电流的抑制作用。

Inhibition of the fast Na+ inward current by the Ca2+ channel blocker tiapamil.

作者信息

Osterrieder W

出版信息

J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1101-6.

PMID:2434733
Abstract

The inhibitory effect of the phenylalkylamine-type Ca2+-entry blocker, tiapamil, on the fast Na+ inward current was investigated in guinea-pig papillary muscles by measuring the maximum upstroke velocity (dV/dt)max of transmembrane action potentials. Tiapamil inhibited (dV/dt)max at concentrations above 10(-6) M, with an IC50 value of 7 X 10(-5) M (1 Hz stimulation frequency, 5.9 mM extracellular K+). Verapamil was less potent in depressing upstroke velocity. Inhibition of the dV/dtmax strongly depended on the frequency at which the muscles were stimulated ("use-dependent" effect). There was no evidence that tiapamil acts in a potential-dependent manner like local anesthetics. The results indicate that the Ca2+-entry blocker tiapamil has additional pharmacological properties, which may contribute to its usefulness in the treatment of ventricular arrhythmias.

摘要

通过测量豚鼠乳头肌跨膜动作电位的最大上升速度(dV/dt)max,研究了苯烷基胺类Ca2+内流阻滞剂替帕米对快速Na+内向电流的抑制作用。替帕米在浓度高于10(-6)M时抑制(dV/dt)max,IC50值为7×10(-5)M(刺激频率1Hz,细胞外K+浓度5.9mM)。维拉帕米降低上升速度的作用较弱。dV/dtmax的抑制强烈依赖于肌肉的刺激频率(“频率依赖性”效应)。没有证据表明替帕米像局部麻醉药那样以电位依赖性方式起作用。结果表明,Ca2+内流阻滞剂替帕米具有其他药理特性,这可能有助于其在治疗室性心律失常方面的应用。

相似文献

1
Inhibition of the fast Na+ inward current by the Ca2+ channel blocker tiapamil.钙通道阻滞剂替帕米对快速钠内向电流的抑制作用。
J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1101-6.
2
Bioelectrical and mechanical effects of tiapamil (Ro 11-1781) on isolated guinea pig myocardium.噻帕米(Ro 11 - 1781)对离体豚鼠心肌的生物电和机械效应。
Cardiovasc Res. 1986 Jan;20(1):42-51. doi: 10.1093/cvr/20.1.42.
3
Tiapamil, a new calcium antagonist. 1. Demonstration of calcium antagonistic activity and related studies.替帕米,一种新型钙拮抗剂。1. 钙拮抗活性的证明及相关研究。
Arzneimittelforschung. 1981;31(9):1393-401.
4
Depressant action of Ca-antagonists on slow action potentials in guinea pig ventricular muscles.钙拮抗剂对豚鼠心室肌慢动作电位的抑制作用。
Acta Physiol Hung. 1986;68(1):51-9.
5
Asocainol, a new antiarrhythmic drug with natrium- and calcium-antagonistic effects on ventricular myocardium.
J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1027-35.
6
Effects of catecholamines on the residual sodium channel dependent slow conduction in guinea pig ventricular muscles under normoxia and hypoxia.儿茶酚胺对常氧和缺氧条件下豚鼠心室肌残余钠通道依赖性缓慢传导的影响。
Cardiovasc Res. 1995 Jan;29(1):65-73.
7
The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.神经保护剂西帕曲明可阻断多种心脏离子通道,并导致心室动作电位呈三角形。
Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1088-96. doi: 10.1111/j.1440-1681.2005.04312.x.
8
Inhibition of ion currents in membrane of sensory neuron by the antiarrhythmic drug BK 129 and selected Ca2+ entry blockers.
Gen Physiol Biophys. 1993 Dec;12(6):517-31.
9
Calcium-antagonist effects of norbormide on isolated perfused heart and cardiac myocytes of guinea-pig: a comparison with verapamil.去甲溴敌隆对豚鼠离体灌注心脏和心肌细胞的钙拮抗剂作用:与维拉帕米的比较。
Br J Pharmacol. 1997 Jan;120(1):19-24. doi: 10.1038/sj.bjp.0700876.
10
Tiapamil reduces the calcium inward current of isolated smooth muscle cells. Dependence on holding potential and pulse frequency.替帕米减少离体平滑肌细胞的内向钙电流。对钳制电位和脉冲频率的依赖性。
Eur J Pharmacol. 1986 Aug 15;127(3):165-71. doi: 10.1016/0014-2999(86)90360-2.

引用本文的文献

1
Calcium channel antagonists. Part V: Second-generation agents.钙通道拮抗剂。第五部分:第二代药物。
Cardiovasc Drugs Ther. 1988 Jul;2(2):191-203. doi: 10.1007/BF00051234.
2
Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.
Cardiovasc Drugs Ther. 1987 Dec;1(4):411-30. doi: 10.1007/BF02209083.